Therapeutic effect of 0.5% thymolol eye drops on rosacea lesions of the face in comparison with placebo

Tehran University of Medical Sciences0 个研究点目标入组 44 人开始时间: 待定最近更新: 2023年2月7日

试验速览

暂无简介。

•Ability to cooperate to refer at the appointed time.
•Ability to cooperate to necessary cooperation in taking the drug.
•consciously understanding the consent and accepting its provisions.
•agreeing not to breastfeed and pregnancy during the study and one month later in women of childbearing age.
•willingness not to take other drugs during the study.
•Have the criteria for diagnosing rosacea.

•Receive any research medication within 30 days prior to enrollment.
•history of allergy to beta-blocker,
•pregnancy or attempt to conceive or breastfeed.
•severe depression.
•history of hypotension or bradycardia,
•history of myocardial infarction or heart failure.
•history of arrhythmia,
•history of asthma or bronchospasm.
•Taking any rosacea stimulant such as calcium channel blocker during the study.
•taking alpha or beta blocker drugs.
•not cooperating in the correct use of the drug or visiting at the appointed time.
•specific exclusion criteria including taking oral or topical drugs such as antibiotics during 3 weeks before Study
•criteria for excluding diagnostic biopsy including lidocaine allergy or a history of hypertrophic or colloidal scarring.

发起方